Reversible sideroblastic anemia associated with the tetracycline analogue COL‐3 | Zendy

Rudek Michelle A. | Zendy; Horne McDonald | Zendy; Figg William D. | Zendy; Dahut William | Zendy; Dyer Valerie | Zendy; Pluda James M. | Zendy; Reed Eddie | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Reversible sideroblastic anemia associated with the tetracycline analogue COL‐3

Author(s) -

Rudek Michelle A.,

Horne McDonald,

Figg William D.,

Dahut William,

Dyer Valerie,

Pluda James M.,

Reed Eddie

Publication year - 2001

Publication title -

american journal of hematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.456

H-Index - 105

eISSN - 1096-8652

pISSN - 0361-8609

DOI - 10.1002/ajh.1076

Subject(s) - medicine , tetracycline , sideroblastic anemia , anemia , bone marrow , cancer , gastroenterology , oncology , biology , antibiotics , genetics

Eight of 35 patients with cancer receiving COL‐3, a tetracycline derivative with antiangiogenic properties, developed anemia while on treatment. All of these patients were enrolled on an approved Phase I clinical trial at the National Cancer Institute. Three of these patients had bone marrow examinations that revealed ringed sideroblasts. This paper describes these cases. Am. J. Hematol. 67:51–53, 2001. Published 2001 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research